Ipamorelin vs GHRP-6

GHRP-6 is a relatively non-selective ghrelin receptor agonist - it activates the full downstream ghrelin pathway, including the hypothalamic hunger circuits that ghrelin naturally controls. Most users feel intense hunger within 15-30 minutes of injection, which is ghrelin doing exactly what ghrelin does. Ipamorelin avoids this because its receptor selectivity is much tighter - it triggers the GH release arm without meaningfully activating the appetite arm. If you want to build muscle without fighting constant hunger, ipamorelin is the answer.

In the pre-Category-2 era, some clinicians used GHRP-6 off-label for appetite stimulation in underweight older adults, chemotherapy recovery, and certain wasting conditions. The appetite effect that makes it uncomfortable for body composition goals is actually useful when you need to eat more. Megestrol acetate and mirtazapine were more common clinical choices, but GHRP-6 had a small niche. That niche has essentially evaporated since September 2023 when 503A compounding of GHRP-6 became prohibited.

Ipamorelin, by a significant margin. At therapeutic doses, ipamorelin produces essentially no cortisol elevation and no prolactin elevation, while GHRP-6 produces both along with the intense hunger spike. Ipamorelin has the cleanest side effect profile of any GHRP on the research market. The only practical upside GHRP-6 offers is the larger acute GH pulse - and even that advantage disappears over a cycle because GHRP-6 desensitizes faster than ipamorelin.

Probably not favorably. The February 2026 FDA reclassification review includes BPC-157, CJC-1295, ipamorelin, and several others, but GHRP-6 is generally expected to remain on Category 2 permanently. The combination of cortisol and prolactin elevation, aggressive appetite side effects, and the availability of cleaner alternatives (ipamorelin, sermorelin) makes it difficult to argue for restoring legal compoundability. This is not a formal FDA position, but it is the broad expectation in the peptide regulatory community.

Ipamorelin works via Selective growth hormone secretagogue that binds to ghrelin receptors to stimulate GH. GHRP-6 works via First-generation growth hormone secretagogue that stimulates GH release and increases appetite via. They differ in FDA approval status, efficacy data, and cost.

Ipamorelin typically costs $35 - $70/mo, while GHRP-6 costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Ipamorelin is not FDA-approved (Category 2 (pending reclassification)). GHRP-6 is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of Ipamorelin include Injection site reactions, Increased hunger, Headache. Common side effects of GHRP-6 include Significant increase in appetite, Water retention, Tingling or numbness. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.